Psychiatric aspects of Parkinson's disease

Psychiatric Annals

Volumn 32, Issue 2, 2002, Pages 99-104

  Menza, Matthew A ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Department of Psychiatry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; IMIPRAMINE; NORTRIPTYLINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR;

AGITATION; AGRANULOCYTOSIS; ANXIETY DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DELUSION; DEMENTIA; DEPRESSION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; ELECTROCONVULSIVE THERAPY; EPIDEMIOLOGICAL DATA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; HYPERSEXUALITY; HYPERTENSION; MANIA; MENTAL DISEASE; MOTION EMOTION CONUNDRUM; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROPATHOLOGY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERSONALITY DISORDER; PREVALENCE; REVIEW; RISK FACTOR; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM;

EID: 0036106571     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20020201-06     Document Type: Review

References (42)

1. Cummings JL. Understanding Parkinson's disease. JAMA. 1999;281:376-378.
2. Friedman JH. Parkinson's disease in the elderly. In: Sage JI, Mark MH, eds. Practical Neurology of the Elderly. New York, NY: Marcel Dekker; 1996:625-663.
3. Cummings JL. Depression and Parkinson's disease. Am J Psychiatry. 1992;149:443-454.
4. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992;55:377-382.
5. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry. 2000;15:644-649.
6. Taylor AE, Saint-Cyr JA, Lang AE, et al. Parkinson's disease and depression: a critical reevaluation. Brain. 1986;109:279-292.
7. Stenager EN, Wermuth L, Stenager E, Boldsen J. Suicide in patients with Parkinson's disease. An epidemiological study. Acta Psychiatr Scand. 1994;90:70-72.
8. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson's disease. Arch Neurol. 1997;54:625-630.
9. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000;15:669-677.
10. Mayberg H, Solomon D. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol. 1995;65:49-60.
11. Jellinger KA. Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm Suppl. 2000;59:185-212.
12. Mayeux R. Depression in the patient with Parkinson's disease. J Clin Psychiatry. 1990;51:20-23.
13. Cantello R, Aguaggia M, Gilli M, et. al. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J Neurol Neurosurg Psychiatry. 1989;52:724-731.
14. Mayeux R, Williams Y. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry. 1986;143:756-759.
15. Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol. 1990;28:57-64.
16. Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol. 1988;45:497-501.
17. Berg D, Supprian T, Hofmann E, et al. Depression in Parkinson's disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol. 1999;246:1186-1193.
18. Menza MA, Robertson-Hoffmann DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993;34:465-470.
19. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol. 1970;23:193-200.
20. Utti RJ, Tanner CM, Pajput AH, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989;12:375-383.
21. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging. 2000;16:365-379.
22. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol. 1988;1:24-36.
23. Kosaka K, Mark MH, Sage JI. Diffuse Lewy body disease. In: Sage JI, Mark MH, eds. Practical Neurology of the Elderly. New York, NY: Marcel Dekker; 1996:697-713.
24. Camp CD. Paralysis agitans, multiple sclerosis and their treatment. In: White WA, Jelliffe SE, Kimpton H, eds. Modern Treatment of Nervous and Mental Disease. Vol 2. Philadelphia, Pa: Lea and Febiger; 1913:651-667.
25. Menza M. The personality associated with Parkinson's disease. Current Psychiatry Reports. 2000;2:421-426.
26. Cloninger RC. A systematic method for clinical description and classification of personality variants. Arch Gen Psychiatry. 1987;44:573-588.
27. Strang RR. Imipramine in treatment of parkinsonism: a double blind placebo study. Br Med J. 1965;2:33-34.
28. Anderson J, Aabro E, Gulmann AE, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand. 1980;62:210-219.
29. Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurol Scand. 1969;45:109-113.
30. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology. 1984;34:1092-1094.
31. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Neurology. 1997;49:1168-1170.
32. Zesiewicz TA, Gold M, Chari G, Hauser RA. Current issues in depression in Parkinson's disease. Am J Geriatr Psychiatry. 1999;7:110-118.
33. Ruggieri S, Stocchi F, Denaro A, Baronti F, Agnoli A. The role of MAO-B inhibitors in the treatment of Parkinson's disease. J Neural Transm Suppl. 1986;22:227-233.
34. Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction. Ann Pharmacother. 1992;26:1300.
35. Douyon R, Serby M, Klutchko B, Rotrosen J. ECT and Parkinson's disease revisited: a "naturalistic" study. Am J Psychiatry. 1989;146:1451-1455.
36. Friedenberg DL, Cummings JL. Parkinson's disease, depression and the on-off phenomenon. Psychosomatics. 1989;30:94-99.
37. Cummings JL. Managing psychosis in patients with Parkinson's disease. N Engl J Med. 1999;340:803.
38. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000;15:201-211.
39. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55:789-794.
40. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340:757-763.
41. Bourke D, Druckenbrod RW. Possible association between donepezil and worsening Parkinson's disease. Ann Pharmacother. 1998;32:610-611.
42. McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry. 2000;15:387-392.